A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

计划入组 31 人 · 首次发布于 2023 年 10 月 24 日

Clonal Hematopoiesis of Indeterminate Potential in Venous Thromboembolism

计划入组 150 人 · 首次发布于 2020 年 7 月 20 日

Clonal Hematopoiesis of Indeterminate Potential in Heart Failure.

计划入组 300 人 · 首次发布于 2024 年 10 月 4 日

CHIP-2

TRPA1 antagonists (Ario Pharma)

Potential Protein Synthesis Inhibitors 11a (Tsinghua University)

PRINCIPAL FOCUSED BLUE CHIP ETF

National Bank of Canada

United Kingdom

Canadian Imperial Bank of Commerce

CHIP and mCAs Linked to Increased Risk of Breast and Colorectal Cancer

Long-term Study Reveals Similar Outcomes for ACS Patients With and Without Traditional Risk Factors

Leukaemia UK Opens Final Project Grant Round Before 2027 Pause, Offering Up to £250,000 for Translational Blood Cancer Research